- Home
- ACLX vs BIRK Comparison
ACLX vs BIRK Comparison
Compare ACLX & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACLX | BIRK |
|---|---|---|
| Founded | 2015 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.0B |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACLX | BIRK |
|---|---|---|
| Price | $115.08 | $41.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $118.17 | $61.43 |
| AVG Volume (30 Days) | ★ 5.0M | 2.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,286,000.00 | N/A |
| Revenue This Year | $342.39 | $13.71 |
| Revenue Next Year | $170.71 | $14.30 |
| P/E Ratio | ★ N/A | $17.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $60.36 | $31.33 |
| 52 Week High | $115.14 | $57.20 |
Technical Indicators
Market Signals| Indicator | ACLX | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 79.86 | 61.00 |
| Support Level | $63.46 | $40.55 |
| Resistance Level | N/A | $42.11 |
| Average True Range (ATR) | 0.11 | 2.12 |
| MACD | -0.62 | 0.28 |
| Stochastic Oscillator | 84.28 | 95.82 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.